Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors.

Morschhauser F, Machiels JP, Salles G, Rottey S, Rule SA, Cunningham D, Peyrade F, Fruchart C, Arkenau HT, Genvresse I, Liu L, Köchert K, Shen K, Kneip C, Peña CE, Grevel J, Zhang J, Cisternas G, Reschke S, Granvil C, Awada A.

Mol Cancer Ther. 2019 Oct 16. pii: molcanther.0466.2019. doi: 10.1158/1535-7163.MCT-19-0466. [Epub ahead of print]

PMID:
31619463
2.

Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial.

Ilson DH, Tabernero J, Prokharau A, Arkenau HT, Ghidini M, Fujitani K, Van Cutsem E, Thuss-Patience P, Beretta GD, Mansoor W, Zhavrid E, Alsina M, George B, Catenacci D, McGuigan S, Makris L, Doi T, Shitara K.

JAMA Oncol. 2019 Oct 10. doi: 10.1001/jamaoncol.2019.3531. [Epub ahead of print]

PMID:
31600365
3.

Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108.

O'Donnell PH, Arkenau HT, Sridhar SS, Ong M, Drakaki A, Spira AI, Zhang J, Gordon MS, Degboe AN, Gupta AK, Mukhopadhyay P, Huang W, Abdullah SE, Angra N, Roskos LK, Guo X, Friedlander T.

Cancer. 2019 Oct 3. doi: 10.1002/cncr.32532. [Epub ahead of print]

PMID:
31581306
4.

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.

Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Pfeiffer P, Orlov S, Lonardi S, Elez E, Kim TW, Schellens JHM, Guo C, Krishnan A, Dekervel J, Morris V, Calvo Ferrandiz A, Tarpgaard LS, Braun M, Gollerkeri A, Keir C, Maharry K, Pickard M, Christy-Bittel J, Anderson L, Sandor V, Tabernero J.

N Engl J Med. 2019 Sep 30. doi: 10.1056/NEJMoa1908075. [Epub ahead of print]

PMID:
31566309
5.

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.

Herbst RS, Arkenau HT, Santana-Davila R, Calvo E, Paz-Ares L, Cassier PA, Bendell J, Penel N, Krebs MG, Martin-Liberal J, Isambert N, Soriano A, Wermke M, Cultrera J, Gao L, Widau RC, Mi G, Jin J, Ferry D, Fuchs CS, Petrylak DP, Chau I.

Lancet Oncol. 2019 Aug;20(8):1109-1123. doi: 10.1016/S1470-2045(19)30458-9. Epub 2019 Jul 10.

PMID:
31301962
6.

Prospective analysis of 895 patients on a UK Genomics Review Board.

Moore DA, Kushnir M, Mak G, Winter H, Curiel T, Voskoboynik M, Moschetta M, Rozumna-Martynyuk N, Balbi K, Bennett P, Forster M, Kulkarni A, Haynes D, Swanton C, Arkenau HT.

ESMO Open. 2019 Mar 21;4(2):e000469. doi: 10.1136/esmoopen-2018-000469. eCollection 2019.

7.

A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas.

Lin CC, Arkenau HT, Lu S, Sachdev J, de Castro Carpeño J, Mita M, Dziadziuszko R, Su WC, Bobilev D, Hughes L, Chan J, Zhang ZY, Weiss GJ.

Br J Cancer. 2019 Jul;121(2):131-138. doi: 10.1038/s41416-019-0503-9. Epub 2019 Jun 20.

8.

A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours.

Mak G, Soria JC, Blagden SP, Plummer R, Fleming RA, Nebot N, Zhang J, Mazumdar J, Rogan D, Gazzah A, Rizzuto I, Greystoke A, Yan L, Tolson J, Auger KR, Arkenau HT.

Br J Cancer. 2019 May;120(10):975-981. doi: 10.1038/s41416-019-0452-3. Epub 2019 Apr 17.

9.

Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study.

Plesner T, Arkenau HT, Gay F, Minnema MC, Boccadoro M, Moreau P, Cavenagh J, Perrot A, Laubach JP, Krejcik J, Ahmadi T, de Boer C, Chen D, Chiu C, Schecter JM, Richardson PG.

Br J Haematol. 2019 Aug;186(3):e35-e39. doi: 10.1111/bjh.15879. Epub 2019 Mar 31. No abstract available.

PMID:
30931524
10.

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.

de Bono JS, Concin N, Hong DS, Thistlethwaite FC, Machiels JP, Arkenau HT, Plummer R, Jones RH, Nielsen D, Windfeld K, Ghatta S, Slomovitz BM, Spicer JF, Yachnin J, Ang JE, Mau-Sørensen PM, Forster MD, Collins D, Dean E, Rangwala RA, Lassen U.

Lancet Oncol. 2019 Mar;20(3):383-393. doi: 10.1016/S1470-2045(18)30859-3. Epub 2019 Feb 8.

PMID:
30745090
11.

Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial.

Chung HC, Arkenau HT, Lee J, Rha SY, Oh DY, Wyrwicz L, Kang YK, Lee KW, Infante JR, Lee SS, Kemeny M, Keilholz U, Melichar B, Mita A, Plummer R, Smith D, Gelb AB, Xiong H, Hong J, Chand V, Safran H.

J Immunother Cancer. 2019 Feb 4;7(1):30. doi: 10.1186/s40425-019-0508-1.

12.

Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study.

Shah MA, Kojima T, Hochhauser D, Enzinger P, Raimbourg J, Hollebecque A, Lordick F, Kim SB, Tajika M, Kim HT, Lockhart AC, Arkenau HT, El-Hajbi F, Gupta M, Pfeiffer P, Liu Q, Lunceford J, Kang SP, Bhagia P, Kato K.

JAMA Oncol. 2019 Apr 1;5(4):546-550. doi: 10.1001/jamaoncol.2018.5441.

PMID:
30570649
13.

Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors.

Bendell JC, Patel MR, Moore KN, Chua CC, Arkenau HT, Dukart G, Harrow K, Liang C.

Oncologist. 2019 Apr;24(4):455-e121. doi: 10.1634/theoncologist.2018-0740. Epub 2018 Nov 26.

14.

Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial.

Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, Alsina M, Ghidini M, Faustino C, Gorbunova V, Zhavrid E, Nishikawa K, Hosokawa A, Yalçın Ş, Fujitani K, Beretta GD, Van Cutsem E, Winkler RE, Makris L, Ilson DH, Tabernero J.

Lancet Oncol. 2018 Nov;19(11):1437-1448. doi: 10.1016/S1470-2045(18)30739-3. Epub 2018 Oct 21. Erratum in: Lancet Oncol. 2018 Dec;19(12):e668.

PMID:
30355453
15.

An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours.

Arkenau HT, Italiano A, Mak G, Toulmonde M, Baird RD, Garcia-Corbacho J, Plummer R, Flynn M, Forster M, Wilson RH, Tosi D, Adenis A, Donaldson K, Posner J, Kawabata I, Arimura A, Deva S, Spicer J.

Eur J Cancer. 2018 Nov;103:17-23. doi: 10.1016/j.ejca.2018.07.134. Epub 2018 Sep 6.

PMID:
30196106
16.

Analysis of a large cohort of non-small cell lung cancers submitted for somatic variant analysis demonstrates that targeted next-generation sequencing is fit for purpose as a molecular diagnostic assay in routine practice.

Moore DA, Balbi K, Ingham A, Arkenau HT, Bennett P.

J Clin Pathol. 2018 Nov;71(11):1001-1006. doi: 10.1136/jclinpath-2018-205319. Epub 2018 Jul 27.

PMID:
30054375
17.

Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF).

Arkenau HT, Martin-Liberal J, Calvo E, Penel N, Krebs MG, Herbst RS, Walgren RA, Widau RC, Mi G, Jin J, Ferry D, Chau I.

Oncologist. 2018 Dec;23(12):1407-e136. doi: 10.1634/theoncologist.2018-0044. Epub 2018 May 31.

18.

A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098.

Brown NF, Williams M, Arkenau HT, Fleming RA, Tolson J, Yan L, Zhang J, Swartz L, Singh R, Auger KR, Lenox L, Cox D, Lewis Y, Plisson C, Searle G, Saleem A, Blagden S, Mulholland P.

Neuro Oncol. 2018 Nov 12;20(12):1634-1642. doi: 10.1093/neuonc/noy078.

PMID:
29788497
19.

Bevacizumab-based first-line chemotherapy in elderly patients with metastatic colorectal cancer: an individual patient data based meta-analysis.

Koch C, Schwing AM, Herrmann E, Borner M, Diaz-Rubio E, Dotan E, Feliu J, Okita N, Souglakos J, Arkenau HT, Porschen R, Koopman M, Punt CJA, de Gramont A, Tournigand C, Zeuzem S, Trojan J.

Oncotarget. 2017 Dec 20;9(12):10272-10283. doi: 10.18632/oncotarget.23475. eCollection 2018 Feb 13.

20.

Towards an optimal treatment algorithm for metastatic pancreatic ductal adenocarcinoma (PDA).

Uccello M, Moschetta M, Mak G, Alam T, Henriquez CM, Arkenau HT.

Curr Oncol. 2018 Feb;25(1):e90-e94. doi: 10.3747/co.25.3708. Epub 2018 Feb 28. Review.

21.

Dynamics of Neutrophils-to-Lymphocyte Ratio Predict Outcomes of PD-1/PD-L1 Blockade.

Moschetta M, Uccello M, Kasenda B, Mak G, McClelland A, Boussios S, Forster M, Arkenau HT.

Biomed Res Int. 2017;2017:1506824. doi: 10.1155/2017/1506824. Epub 2017 Nov 28.

22.

Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumours.

Nebot N, Arkenau HT, Infante JR, Chandler JC, Weickhardt A, Lickliter JD, Sarantopoulos J, Gordon MS, Mak G, St-Pierre A, Tang L, Mookerjee B, Carson SW, Hayes S, Grossmann KF.

Br J Clin Pharmacol. 2018 Apr;84(4):764-775. doi: 10.1111/bcp.13488. Epub 2018 Jan 23.

23.

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.

Dirix LY, Takacs I, Jerusalem G, Nikolinakos P, Arkenau HT, Forero-Torres A, Boccia R, Lippman ME, Somer R, Smakal M, Emens LA, Hrinczenko B, Edenfield W, Gurtler J, von Heydebreck A, Grote HJ, Chin K, Hamilton EP.

Breast Cancer Res Treat. 2018 Feb;167(3):671-686. doi: 10.1007/s10549-017-4537-5. Epub 2017 Oct 23.

24.

SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting.

Greystoke A, Steele N, Arkenau HT, Blackhall F, Md Haris N, Lindsay CR, Califano R, Voskoboynik M, Summers Y, So K, Ghiorghiu D, Dymond AW, Hossack S, Plummer R, Dean E.

Br J Cancer. 2017 Sep 26;117(7):938-946. doi: 10.1038/bjc.2017.271. Epub 2017 Aug 24.

25.

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.

Powles T, O'Donnell PH, Massard C, Arkenau HT, Friedlander TW, Hoimes CJ, Lee JL, Ong M, Sridhar SS, Vogelzang NJ, Fishman MN, Zhang J, Srinivas S, Parikh J, Antal J, Jin X, Gupta AK, Ben Y, Hahn NM.

JAMA Oncol. 2017 Sep 14;3(9):e172411. doi: 10.1001/jamaoncol.2017.2411. Epub 2017 Sep 14.

26.

A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors.

Mateo J, Ganji G, Lemech C, Burris HA, Han SW, Swales K, Decordova S, DeYoung MP, Smith DA, Kalyana-Sundaram S, Wu J, Motwani M, Kumar R, Tolson JM, Rha SY, Chung HC, Eder JP, Sharma S, Bang YJ, Infante JR, Yan L, de Bono JS, Arkenau HT.

Clin Cancer Res. 2017 Oct 1;23(19):5981-5992. doi: 10.1158/1078-0432.CCR-17-0725. Epub 2017 Jun 23.

27.

Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.

Choueiri TK, Plimack E, Arkenau HT, Jonasch E, Heng DYC, Powles T, Frigault MM, Clark EA, Handzel AA, Gardner H, Morgan S, Albiges L, Pal SK.

J Clin Oncol. 2017 Sep 10;35(26):2993-3001. doi: 10.1200/JCO.2017.72.2967. Epub 2017 Jun 23.

PMID:
28644771
28.

Biological and predictive role of ERCC1 polymorphisms in cancer.

Formica V, Doldo E, Antonetti FR, Nardecchia A, Ferroni P, Riondino S, Morelli C, Arkenau HT, Guadagni F, Orlandi A, Roselli M.

Crit Rev Oncol Hematol. 2017 Mar;111:133-143. doi: 10.1016/j.critrevonc.2017.01.016. Epub 2017 Jan 28. Review.

PMID:
28259288
29.

Second-Line Combination Therapies in Pancreatic Cancer: Where Are We Now?

Uccello M, Moschetta M, Arkenau HT.

J Clin Oncol. 2017 Apr 20;35(12):1370-1371. doi: 10.1200/JCO.2016.71.0921. Epub 2017 Jan 23. No abstract available.

PMID:
28113022
30.

Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer.

Moschetta M, Mak G, Hauser J, Davies C, Uccello M, Arkenau HT.

Exp Hematol Oncol. 2017 Jan 10;6:1. doi: 10.1186/s40164-016-0061-2. eCollection 2017.

31.

A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors.

Soria JC, Gan HK, Blagden SP, Plummer R, Arkenau HT, Ranson M, Evans TR, Zalcman G, Bahleda R, Hollebecque A, Lemech C, Dean E, Brown J, Gibson D, Peddareddigari V, Murray S, Nebot N, Mazumdar J, Swartz L, Auger KR, Fleming RA, Singh R, Millward M.

Ann Oncol. 2016 Dec;27(12):2268-2274. doi: 10.1093/annonc/mdw427. Epub 2016 Oct 11.

PMID:
27733373
32.

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Plesner T, Arkenau HT, Gimsing P, Krejcik J, Lemech C, Minnema MC, Lassen U, Laubach JP, Palumbo A, Lisby S, Basse L, Wang J, Sasser AK, Guckert ME, de Boer C, Khokhar NZ, Yeh H, Clemens PL, Ahmadi T, Lokhorst HM, Richardson PG.

Blood. 2016 Oct 6;128(14):1821-1828. doi: 10.1182/blood-2016-07-726729. Epub 2016 Aug 16.

33.

Erratum to: Development and Evaluation of a New Technological Way of Engaging Patients and Enhancing Understanding of Drug Tolerability in Early Clinical Development: PROACT.

Hughes A, Landers D, Arkenau HT, Shah S, Stephens R, Mahal A, Simmons M, Lemech C, Royle J.

Adv Ther. 2016 Sep;33(9):1677-1678. No abstract available.

34.

Enumeration and Molecular Characterisation of Circulating Tumour Cells in Endometrial Cancer.

Lemech CR, Ensell L, Paterson JC, Eminowicz G, Lowe H, Arora R, Arkenau HT, Widschwendter M, MacDonald N, Olaitan A, Mould T, Meyer T, Hartley J, Mitra A, Ledermann JA, McCormack M, Kristeleit RS.

Oncology. 2016;91(1):48-54. doi: 10.1159/000445999. Epub 2016 Jun 3.

PMID:
27256106
35.

Development and Evaluation of a New Technological Way of Engaging Patients and Enhancing Understanding of Drug Tolerability in Early Clinical Development: PROACT.

Hughes A, Landers D, Arkenau HT, Shah S, Stephens R, Mahal A, Simmons M, Lemech C, Royle J.

Adv Ther. 2016 Jun;33(6):1012-24. doi: 10.1007/s12325-016-0335-4. Epub 2016 May 11. Erratum in: Adv Ther. 2016 Sep;33(9):1677-8.

36.

Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors.

Bendell JC, Patel MR, Yoshida K, Seraj J, Weaver R, Lemech C, Todaro TG, Pant S, Arkenau HT.

Cancer Chemother Pharmacol. 2016 Jun;77(6):1275-83. doi: 10.1007/s00280-016-3031-9. Epub 2016 May 5.

37.

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.

Chatterjee M, Turner DC, Felip E, Lena H, Cappuzzo F, Horn L, Garon EB, Hui R, Arkenau HT, Gubens MA, Hellmann MD, Dong D, Li C, Mayawala K, Freshwater T, Ahamadi M, Stone J, Lubiniecki GM, Zhang J, Im E, De Alwis DP, Kondic AG, Fløtten Ø.

Ann Oncol. 2016 Jul;27(7):1291-8. doi: 10.1093/annonc/mdw174. Epub 2016 Apr 26.

38.

Reporting incidental germline variants in the context of day-to-day somatic genomic profiling.

Mak G, Moschetta M, Arkenau HT.

Ann Oncol. 2016 May;27(5):758-9. doi: 10.1093/annonc/mdw078. Epub 2016 Feb 23. No abstract available.

PMID:
26912559
39.

Complexity of FGFR signalling in metastatic urothelial cancer.

Rodriguez-Vida A, Saggese M, Hughes S, Rudman S, Chowdhury S, Smith NR, Lawrence P, Rooney C, Dougherty B, Landers D, Kilgour E, Arkenau HT.

J Hematol Oncol. 2015 Oct 24;8:119. doi: 10.1186/s13045-015-0221-6.

40.

Immunotherapy for bladder cancer: rediscovering an old friend.

Voskoboynik M, Rudman S, Arkenau HT, Hughes S, Chowdhury S.

BJU Int. 2016 May;117(5):721-4. doi: 10.1111/bju.13330. Epub 2015 Oct 20. No abstract available.

41.

Evaluation of CYP3A-mediated drug-drug interactions with romidepsin in patients with advanced cancer.

Laille E, Patel M, Jones SF, Burris HA 3rd, Infante J, Lemech C, Liu L, Arkenau HT.

J Clin Pharmacol. 2015 Dec;55(12):1378-85. doi: 10.1002/jcph.560. Epub 2015 Jul 29.

42.

The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation.

Lolkema MP, Bohets HH, Arkenau HT, Lampo A, Barale E, de Jonge MJA, van Doorn L, Hellemans P, de Bono JS, Eskens FALM.

Clin Cancer Res. 2015 May 15;21(10):2297-2304. doi: 10.1158/1078-0432.CCR-14-3258. Epub 2015 Mar 5.

43.

Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib.

Suttle AB, Grossmann KF, Ouellet D, Richards-Peterson LE, Aktan G, Gordon MS, LoRusso PM, Infante JR, Sharma S, Kendra K, Patel M, Pant S, Arkenau HT, Middleton MR, Blackman SC, Botbyl J, Carson SW.

J Clin Pharmacol. 2015 Apr;55(4):392-400. doi: 10.1002/jcph.437. Epub 2014 Dec 30.

PMID:
25449654
44.

Clinical impact of checkpoint inhibitors as novel cancer therapies.

Shih K, Arkenau HT, Infante JR.

Drugs. 2014 Nov;74(17):1993-2013. doi: 10.1007/s40265-014-0305-6. Review.

45.

Patients' perceptions of research biopsies in phase I oncology trials.

Lemech C, Dua D, Newmark J, Saggese M, Simmons E, Spiliopoulou P, Arkenau HT.

Oncology. 2015;88(2):95-102. doi: 10.1159/000368161. Epub 2014 Oct 14.

PMID:
25322682
46.

Rationally designed treatment for metastatic colorectal cancer: current drug development strategies.

Spiliopoulou P, Arkenau HT.

World J Gastroenterol. 2014 Aug 14;20(30):10288-95. doi: 10.3748/wjg.v20.i30.10288. Review.

47.

Improving patient selection for phase I oncology trials.

Voskoboynik M, Arkenau HT.

J Clin Oncol. 2014 Oct 1;32(28):3198-9. doi: 10.1200/JCO.2014.55.8031. Epub 2014 Jul 28. No abstract available.

PMID:
25071142
48.

Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436).

Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau HT, Brown MP, Hamid O, Infante JR, Millward M, Pavlick A, Chin MT, O'Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF.

Clin Cancer Res. 2014 Sep 1;20(17):4449-58. doi: 10.1158/1078-0432.CCR-14-0887. Epub 2014 Jun 23.

49.

Resistance surveillance in a BRAF mutant melanoma patient on long-term BRAF-inhibitor treatment.

Mak G, Arkenau HT, Chin M.

Melanoma Res. 2014 Aug;24(4):408-12. doi: 10.1097/CMR.0000000000000085.

50.

Combination therapies for the treatment of advanced melanoma: a review of current evidence.

Voskoboynik M, Arkenau HT.

Biochem Res Int. 2014;2014:307059. doi: 10.1155/2014/307059. Epub 2014 Feb 12. Review.

Supplemental Content

Loading ...
Support Center